Abstract:Objective To study the effect of rosiglitazone,a specific ligand of peroxisome prolif erator-activatcd receptor gamma (PPARγ),on the biological characters of activation hepatic stellate cells (HSCs).Methods The activated HSCs were divided into four groups:control,3 μM rosiglitazone group,10 μM rosigtitazone group and 20μM rosiglitazone group.The cell proliferation was determined with MTT colorimetric assay.The expression at mRNA level of PPARγ,TGF-β1,and type Ⅰpro-collagen was detected by RT-PCR.The expression of proteins of PPARγ,TGF-β1,type Ⅰ and Ⅲcollagen was detected by Western blot.α-smooth muscle actin (α-SMA) of HSCs was detected with immunocytochemistry.Type Ⅰ collagen in the supernatant of cultured HSCs was measured by EIASA.Results 1)The expression of PPARγ at mRNA level markedly increased in HSCs of 20 μM and 10 μM rosiglitazone group than 3 μM and control group (P＜0.01),while typeⅠ pro-collagen decreased in HSCs of 20 μM and 10 μM rosiglitazone group (P＜0.01).The difference of the expression of PPARγ and type Ⅰ pro-collagen at mRNA level was not significant between 10 μM rosiglitazone group and 20 μmol/L rosiglitazone group(P＞0.05).Neither was it between control and3 μM rosiglitazone group(P＞0.05).2)The expression of proteins of PPART,TGF-β1 and type Ⅰ collagen was accordant with that of mRNA.The expression of type Ⅲ was not significantly different among the 4 groups(P＞0.05).3)The staining of α-SMA in HSCs markedly decreased in 20 μM and 10 μM rosiglitazone group than that of control and 3 μM rosiglitazone group(P＜0.05).There was no significant difference between 20μM and 10μM rosiglitazone group.Neither was it between 10μM rosiglitazone group and control group(P＞0.05).4)Type Ⅰ collagen in the supernatant of cultured HSCs in 20μM and 10 μM rosiglitazone group markedly decreased than that in control and 3 μM rosiglitazone group(P＜0.01).There was no significant difference between 20μM and 10μM rosiglitazone group.Neither was it between 10μM rosiglitazone group and control group(P＞0.05).Conclusion By increasing expression of PPARγ in activated HSCs,roziglitazone,a specific agonist of PPARγ,decreases α-SMA expression and collagen synthesis,inhibits proliferation and attenuates the production of type Ⅰ collagen.These results demonstrated that the activation of HSCs can be suppressed.

Rosiglitazone inhibits advanced glycosylation end-human serum albumin induced immune maturation of dendritic cells

Rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products

Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

Rosiglitazone attenuates endothelial progenitor cell apoptosis induced by TNF-α via ERK/MAPK and NF-κB signal pathways.

Effects of Rosiglitazone on Serum Levels of Lipids and Inflammatory Factors in Atherosclerotic Rats

Insulin-Attenuated Inflammatory Response of Dendritic Cells in Diabetes by Regulating RAGE-PKCβ1-IRS1-NF-κB Signal Pathway: A Study on the Anti-Inflammatory Mechanism of Insulin in Diabetes

Rosiglitazone Ameliorates Senescence-Like Phenotypes in a Cellular Photoaging Model.

Peroxisome proliferator-activated receptor gamma preserves intracellular homeostasis of insulin-resistant periodontal ligament stem cells

Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease

Mechanism of Rosiglitazone Suppressing the Activation of Hepatic Stellate Cells

Effects of rosiglitazone on expressions of peroxisome proliferator-activated receptor gamma and TGF-β1 in rats with adriamycin nephrosis

A specific ligand of peroxisome proliferator-activated receptor gamma suppressing activation of hepatic stellate cells

Rosiglitazone Impedes Porphyromonas Gingivalis-Accelerated Atherosclerosis by Downregulating the TLR/NF-κB Signaling Pathway in Atherosclerotic Mice

PPARγ Agonist Rosiglitazone Suppresses Renal Mpges-1/Pge2 Pathway in Db/db Mice

Peroxisome Proliferator–activated Receptor-Γ Agonist Rosiglitazone Reduces Clinical Inflammatory Responses in Type 2 Diabetes with Coronary Artery Disease after Coronary Angioplasty

Monascin and AITC attenuate methylglyoxal-induced PPARγ phosphorylation and degradation through inhibition of the oxidative stress/PKC pathway depending on Nrf2 activation

Rosiglitazone Inhibits Angiotensin Ii-Induced Ctgf Expression in Vascular Smooth Muscle Cells - Role of Ppar-Gamma in Vascular Fibrosis

Effects of Peroxisome Proliferators-Activatied Receptor Gamma on the Biological Characteristics of Hepatic Stellate Cells

The effects of Rosiglitazone on the levels of cytokine in patients with IGT and metabolic syndrome

Effects of peroxisome proliferator-activated receptor gamma on airway mucus production in a murine model of asthma

Rosiglitazone attenuates hypoxia-induced renal cell apoptosis by inhibiting NF-κB signaling pathway in a PPARγ-dependent manner